Venetoclax Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

  • STATUS
    Recruiting
  • End date
    Jun 1, 2022
  • participants needed
    77
  • sponsor
    Nordic Lymphoma Group
Updated on 20 October 2021

Summary

Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.

Details
Condition Relapsed Non Hodgkin Lymphoma
Treatment venetoclax
Clinical Study IdentifierNCT03505944
SponsorNordic Lymphoma Group
Last Modified on20 October 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note